{
    "clinical_study": {
        "@rank": "146158", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the routine clinical use and the safety and efficacy\n      of Xeloda (capecitabine) in patients with metastatic or advanced breast cancer. Eligible\n      patients will be followed for up to 24 months."
        }, 
        "brief_title": "An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic or Advanced Breast Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult female patients, >/= 18 years of age\n\n          -  Cytolologic/histopathologic confirmed diagnosis of metastatic breast cancer\n\n          -  Prescribed Xeloda as in routine clinical practice\n\n          -  Informed consent signed\n\n        Exclusion Criteria:\n\n          -  Participation in any other clinical trial\n\n          -  History of severe and unexpected reactions to fluoropyrimidine therapy\n\n          -  Hypersensitivity to capecitabine or to any of the excipients of fluorouracil\n\n          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency\n\n          -  Pregnant or lactating women\n\n          -  Severe leucopenia, neutropenia, or thrombocytopenia\n\n          -  Severe hepatic impairment\n\n          -  Severe renal impairment (creatinine clearance below 30 ml/min)\n\n          -  Treatment with sorivudine or its chemically related analogues, such as brivudine\n\n          -  Refusal to give consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic breast cancer initiated on therapy with Xeloda"
            }
        }, 
        "enrollment": {
            "#text": "274", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725386", 
            "org_study_id": "ML25640"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Abbottabad", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Faisalabad", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gujranwala", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Islamabad", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Islamabad", 
                        "country": "Pakistan", 
                        "zip": "44000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "zip": "74700"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "zip": "75500"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lahore", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lahore", 
                        "country": "Pakistan", 
                        "zip": "54600"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Multan", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peshwar", 
                        "country": "Pakistan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rawalpindi", 
                        "country": "Pakistan", 
                        "zip": "46000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rawalpindi", 
                        "country": "Pakistan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Pakistan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Study on Xeloda to Document Its Use in Routine Practice in Patients With Metastatic or Advanced Breast Cancer", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Pakistan: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Xeloda dosage/schedule in routine clinical practice", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Regimen/concomitant medication used in routine clinical practice", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}